Pathologic classification of peripheral nerve tumors

Neurosurgery Clinics of North America

Volumn 15, Issue 2, 2004, Pages 157-166

  Skovronsky, Daniel M ^a   Oberholtzer, John Carl ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HEMOSIDERIN; MERLIN; PROTEIN S 100;

CANCER GENETICS; CARCINOGENESIS; CELL DIFFERENTIATION; CHROMOSOME 22; DISEASE COURSE; GANGLIONEUROMA; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NERVE CELL; NERVE PLEXUS; NERVE SHEATH TUMOR; NERVE TUMOR; NEURILEMOMA; NEUROFIBROMA; NONHUMAN; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHWANN CELL; SPINDLE CELL; TUMOR CLASSIFICATION;

GANGLIONEUROMA; HUMANS; NERVE SHEATH NEOPLASMS; NEURILEMMOMA; NEUROFIBROMA; PERIPHERAL NERVOUS SYSTEM NEOPLASMS;

EID: 2942538212     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2004.02.005     Document Type: Review

References (42)

1. Kleihues P., Cavenee W.K. Pathology and genetics of tumours of the nervous system. World Health Organization classification of tumours. 2000;IARC Press, Lyon
2. Scheithauer B.W., Woodruff J.M., Erlandson R.A. Tumors of the peripheral nervous system. vol. 24:1999;Armed Forces Institute of Pathology, Washington, DC
3. Burger P.C., Scheithauer B.W., Vogel F.S. The peripheral nervous system. Surgical pathology of the nervous system and its coverings. 4th edition:2002;579-640 Churchill Livingstone, New York
4. Casadei G.P., Scheithauer B.W., Hirose T., Manfrini M., Van Houton C., Wood M.B. Cellular schwannoma A. clinicopathologic, DNA flow cytometric, and proliferation marker study of 70 patients. Cancer. 75:(5):1995;1109-1119
5. Fletcher C.D., Davies S.E. Benign plexiform (multinodular) schwannoma: a rare tumour unassociated with neurofibromatosis. Histopathology. 10:(9):1986;971-980
6. Ishida T., Kuroda M., Motoi T., Oka T., Imamura T., Machinami R. Phenotypic diversity of neurofibromatosis 2: association with plexiform schwannoma. Histopathology. 32:(3):1998;264-270
7. Kurtkaya-Yapicier O., Scheithauer B., Woodruff J.M. The pathobiologic spectrum of schwannomas. Histol Histopathol. 18:(3):2003;925-934
8. Noubari B.A., Chiaramonte I., Magro G., Tropea R., Mancuso P. Spinal malignant melanotic schwannoma. Case report. J Neurosurg Sci. 42:(4):1998;245-249
9. Trofatter J.A., MacCollin M.M., Rutter J.L., Murrell J.R., Duyao M.P., Parry D.M., et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 72:(5):1993;791-800
10. Twist E.C., Ruttledge M.H., Rousseau M., Sanson M., Papi L., Merel P., et al. The neurofibromatosis type 2 gene is inactivated in schwannomas. Hum Mol Genet. 3:(1):1994;147-151
11. Xiao G.H., Chernoff J., Testa J.R. NF2: the wizardry of merlin. Genes Chromosomes Cancer. 38:(4):2003;389-399
12. Stemmer-Rachamimov A.O., Xu L., Gonzalez-Agosti C., Burwick J.A., Pinney D., Beauchamp R., et al. Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol. 151:(6):1997;1649-1654
13. Shaw R.J., Paez J.G., Curto M., Yaktine A., Pruitt W.M., Saotome I., et al. The NF2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 1:(1):2001;63-72
14. MacCollin M., Woodfin W., Kronn D., Short M.P. Schwannomatosis: a clinical and pathologic study. Neurology. 46:(4):1996;1072-1079
15. Jacoby L.B., Jones D., Davis K., Kronn D., Short M.P., Gusella J., et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet. 61:(6):1997;1293-1302
16. MacCollin M., Willett C., Heinrich B., Jacoby L.B., Acierno J.S. Jr., Perry A., et al. Familial schwannomatosis: exclusion of the NF2 locus as the germline event. Neurology. 60:(12):2003;1968-1974
17. Kirschner L.S., Carney J.A., Pack S.D., Taymans S.E., Giatzakis C., Cho Y.S., et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet. 26:(1):2000;89-92
18. Stergiopoulos S.G., Stratakis C.A. Human tumors associated with Carney complex and germline PRKAR1A mutations: a protein kinase A disease. FEBS Lett. 546:(1):2003;59-64
19. Marchuk D.A., Saulino A.M., Tavakkol R., Swaroop M., Wallace M.R., Andersen L.B., et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics. 11:(4):1991;931-940
20. Gutmann D.H., Wood D.L., Collins F.S. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA. 88:(21):1991;9658-9662
21. Rey I., Hall A. Tumour suppressors and the regulation of GTP-binding protein activity. Trends Cell Biol. 3:(2):1993;43-46
22. Xu G.F., Lin B., Tanaka K., Dunn D., Wood D., Gesteland R., et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 63:(4):1990;835-841
23. Tong J., Hannan F., Zhu Y., Bernards A., Zhong Y. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci. 5:(2):2002;95-96
24. Dasgupta B., Gutmann D.H. Neurofibromatosis 1: closing the GAP between mice and men. Curr Opin Genet Dev. 13:(1):2003;20-27
25. Brannan C.I., Perkins A.S., Vogel K.S., Ratner N., Nordlund M.L., Reid S.W., et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 8:(9):1994;1019-1029
26. Vogel K.S., Klesse L.J., Velasco-Miguel S., Meyers K., Rushing E.J., Parada L.F. Mouse tumor model for neurofibromatosis type 1. Science. 286:(5447):1999;2176-2179
27. Zhu Y., Ghosh P., Charnay P., Burns D.K., Parada L.F. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 296:(5569):2002;920-922
28. Bajenaru M.L., Hernandez M.R., Perry A., Zhu Y., Parada L.F., Garbow J.R., et al. Optic nerve glioma in mice requires astrocyte NF1 gene inactivation and NF1 brain heterozygosity. Cancer Res. 63:(24):2003;8573-8577
29. Zhu Y., Parada L.F. The molecular and genetic basis of neurological tumours. Nat Rev Cancer. 2:(8):2002;616-626
30. Cichowski K., Shih T.S., Schmitt E., Santiago S., Reilly K., McLaughlin M.E., et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 286:(5447):1999;2172-2176
31. Yang F.C., Ingram D.A., Chen S., Hingtgen C.M., Ratner N., Monk K.R., et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest. 112:(12):2003;1851-1861
32. Viskochil D.H. It takes two to tango: mast cell and Schwann cell interactions in neurofibromas. J Clin Invest. 112:(12):2003;1791-1793
33. Tsang W.Y., Chan J.K., Chow L.T., Tse C.C. Perineurioma: an uncommon soft tissue neoplasm distinct from localized hypertrophic neuropathy and neurofibroma. Am J Surg Pathol. 16:(8):1992;756-763
34. Emory T.S., Scheithauer B.W., Hirose T., Wood M., Onofrio B.M., Jenkins R.B. Intraneural perineurioma. A clonal neoplasm associated with abnormalities of chromosome 22. Am J Clin Pathol. 103:(6):1995;696-704
35. Giannini C., Scheithauer B.W., Jenkins R.B., Erlandson R.A., Perry A., Borell T.J., et al. Soft-tissue perineurioma. Evidence for an abnormality of chromosome 22, criteria for diagnosis, and review of the literature. Am J Surg Pathol. 21:(2):1997;164-173
36. Wick M.R., Swanson P.E., Scheithauer B.W., Manivel J.C. Malignant peripheral nerve sheath tumor. An immunohistochemical study of 62 cases. Am J Clin Pathol. 87:(4):1987;425-433
37. Ducatman B.S., Scheithauer B.W. Malignant peripheral nerve sheath tumors with divergent differentiation. Cancer. 54:(6):1984;1049-1057
38. Woodruff J.M. Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Am J Med Genet. 89:(1):1999;23-30
39. Birindelli S., Perrone F., Oggionni M., Lavarino C., Pasini B., Vergani B., et al. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest. 81:(6):2001;833-844
40. Nielsen G.P., Stemmer-Rachamimov A.O., Ino Y., Moller M.B., Rosenberg A.E., Louis D.N. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 155:(6):1999;1879- 1884
41. Halling K.C., Scheithauer B.W., Halling A.C., Nascimento A.G., Ziesmer S.C., Roche P.C., et al. p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am J Clin Pathol. 106:(3):1996;282-288
42. Zhou H., Coffin C.M., Perkins S.L., Tripp S.R., Liew M., Viskochil D.H. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am J Surg Pathol. 27:(10):2003;1337-1345